The new Wisconsin Opioid Overdose Response Center is already making important strides toward its mission to equip Wisconsin pharmacies with innovative tools to prevent opioid deaths.
A team of UW–Madison scientists have uncovered that bile acids produced by the liver to help digest food may affect our risk for developing colon cancer.
An interdisciplinary group of researchers will will investigate the biological processes that promote lung scarring. With the aid of artificial intelligence and advanced 3D modeling, they will also develop and refine new imaging techniques and drug delivery systems that could aid in halting its progression.
Mice treated with the therapeutic-laden bacteria experienced delayed tumor growth and significantly longer survival compared with mice that received other treatments.
The work centers around altering the interaction between two proteins that are believed to be involved in setting the stage for diseases like Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis, or ALS.
Researchers uncovered a previously unknown function of a protein that is central to gut health and implicated in the development of colitis, a severe and chronic form of IBD.
The PharmD Early Assurance program provides conditional admission to the UW–Madison Doctor of Pharmacy (PharmD) program for high school seniors who want to become a pharmacist and are admitted to a four-year UW System university.
Mapping variations in antibiotic resistance could help patients receive better informed treatment decisions from their health care providers.
The multidisciplinary team of researchers found that BDGR-49 protects mice infected with deadly eastern equine encephalitis virus (EEEV) or Venezuelan equine encephalitis virus (VEEV).
Twelve faculty members have been chosen to receive this year’s Distinguished Teaching Awards, an honor given out since 1953 to recognize some of the university’s finest educators.
Researchers found that in mice that received the engineered proteins via intravenous injections, the proteins led to clot formation almost exclusively within tumors, with only very limited thrombosis occurring elsewhere.
Doctors, nurses and pharmacists educated and trained in the UW’s health sciences programs are working in every one of the state’s 72 counties.
School of Pharmacy and School of Medicine and Public Health collaborators are leading two first-in-kind clinical psilocybin trials for treating opioid and methamphetamine use disorders.
UW researchers demonstrate just how much promise some well-equipped bacteria hold for improved inflammatory bowel disease treatments.
UW–Madison researchers have developed a powerful immunity-boosting postoperative treatment that could transform the odds for patients with glioblastoma.
The gel, tested in mice, releases drugs and special antibodies that simultaneously deplete immune-blocking cells called macrophages from the surgical site and activate T cells so they can attack cancer.
UW–Madison School of Pharmacy students concluded that just 15% of CBD-infused oil, beverages and other products are labeled correctly, based on a survey of stores in Southwestern Wisconsin.
High activity of the gene, Nrf2, slowed cognitive and physical decline in the mice and reduced the accumulation of sticky proteins in their brains, all key markers of the disease in humans.
Researchers in the School of Pharmacy, led by Quanyin Hu, have developed a system that can keep probiotic bacteria alive in the lower intestine long enough to help treat or prevent colitis in a mouse model of the disease.
These scholarships will be awarded to students pursuing a master’s degree in Pharmaceutical Sciences: Applied Drug Development or Psychoactive Pharmaceutical Investigation who demonstrate a financial need and/or have a strong commitment to diversity, equity and inclusion.